论文部分内容阅读
目的分析并研究卡培他滨与替吉奥维持治疗在晚期胃癌患者治疗中应用的临床效果和不良反应。方法 68例晚期胃癌患者,随机分为观察组和对照组,各34例。对照组患者采用卡培他滨治疗,观察组患者采用替吉奥治疗,观察并比较两组患者的治疗效果和不良反应。结果观察组患者的客观有效率(RR)为32.35%(11/34),肿瘤控制率(TGCR)为52.94%(18/34),中位无疾病进展时间(PFS)为(4.5±1.2)个月,中位总生存时间(OS)为(7.6±2.1)个月;对照组患者的RR为35.29%(12/34),TGCR为50.00%(17/34),PFS为(4.6±1.5)个月,OS为(7.8±2.3)个月,两组患者RR、TGCR、PFS、OS指标比较差异无统计学意义(P>0.05)。观察组血液学不良反应总发生率为14.71%,非血液学不良反应总发生率为0,均低于对照组的38.24%、23.53%,差异均具有统计学意义(P<0.05)。结论临床上对晚期胃癌患者进行维持治疗,给予替吉奥治疗的患者不良反应更小,可以为患者提供更好的感受,值得推广使用。
Objective To analyze and study the clinical effects and adverse reactions of capecitabine and tioguan sustained treatment in the treatment of patients with advanced gastric cancer. Methods Sixty-eight patients with advanced gastric cancer were randomly divided into observation group and control group, 34 cases in each. Patients in the control group were treated with capecitabine, and patients in the observation group were treated with tirofiban. The therapeutic effects and adverse reactions in both groups were observed and compared. Results The objective effective rate (RR) of the observation group was 32.35% (11/34), the tumor control rate (TGCR) was 52.94% (18/34) and the median progression-free time (PFS) Months, the median overall survival time (OS) was (7.6 ± 2.1) months. In the control group, RR was 35.29% (12/34), TGCR was 50.00% (17/34), PFS was (4.6 ± 1.5) ) Months, OS was (7.8 ± 2.3) months. There was no significant difference in RR, TGCR, PFS and OS between two groups (P> 0.05). The total incidence of adverse reactions in the observation group was 14.71%, the incidence of non-hematologic adverse reactions was 0, which was lower than that of the control group (38.24%, 23.53%, respectively) (P <0.05). Conclusions The patients with advanced gastric cancer are treated with maintenance therapy clinically. The patients treated with tirofiban have less adverse reactions, which can provide patients with better feelings and are worth popularizing.